[HTML][HTML] Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer …

YY Shao, SY Wang, SM Lin, KY Chen, JH Tseng… - Journal of the Formosan …, 2021 - Elsevier
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan.
The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had …

[HTML][HTML] 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

ML Yu, PJ Chen, CY Dai, TH Hu, CF Huang… - Journal of the Formosan …, 2020 - Elsevier
Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in
Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy …

A family of tissue-specific resistin-like molecules

CM Steppan, EJ Brown, CM Wright… - Proceedings of the …, 2001 - National Acad Sciences
We have identified a family of resistin-like molecules (RELMs) in rodents and humans.
Resistin is a hormone produced by fat cells. RELMα is a secreted protein that has a …

[HTML][HTML] An overview on thermosensitive oral gel based on poloxamer 407

Y Chen, JH Lee, M Meng, N Cui, CY Dai, Q Jia, ES Lee… - Materials, 2021 - mdpi.com
In this review, we describe the application of thermosensitive hydrogels composed of
poloxamer in medicine, especially for oral cavities. Thermosensitive hydrogels remain fluid …

[HTML][HTML] Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial

ML Yu, CY Dai, JF Huang, CF Chiu, YHC Yang… - …, 2008 - Wiley Online Library
Recommended treatment for hepatitis C virus genotype 1 (HCV‐1) patients is peginterferon
plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as …

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

ML Yu, CY Dai, JF Huang, NJ Hou, LP Lee, MY Hsieh… - Gut, 2007 - gut.bmj.com
Background: The recommended treatment for patients infected with hepatitis C virus
genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks. Aim …

OxLDL up‐regulates microRNA‐29b, leading to epigenetic modifications of MMP‐2/MMP‐9 genes: a novel mechanism for cardiovascular diseases

KC Chen, YS Wang, CY Hu, WC Chang… - The FASEB …, 2011 - Wiley Online Library
MicroRNAs (miRNAs), small noncoding RNAs, can control gene expression by binding to
their target genes for degradation and/or translational repression. Epigenetic mechanisms …

Experimental realization of universal geometric quantum gates with solid-state spins

C Zu, WB Wang, L He, WG Zhang, CY Dai, F Wang… - Nature, 2014 - nature.com
Experimental realization of a universal set of quantum logic gates is the central requirement
for the implementation of a quantum computer. In an 'all-geometric'approach to quantum …

A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide …

ML Yu, SM Lin, WL Chuang, CY Dai… - Antiviral …, 2006 - journals.sagepub.com
Background The long-term benefit for chronic hepatitis C (CHC) patients treated with
interferon (IFN)/ribavirin (RBV) combination therapy remains unclear. We aimed to evaluate …

[PDF][PDF] Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition

S Nakagawa, L Wei, WM Song, T Higashi, S Ghoshal… - Cancer cell, 2016 - cell.com
Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second most lethal
cancer worldwide. HCC prediction and prevention in cirrhosis are key unmet medical needs …